Partnering is central to our corporate development strategy. argenx selectively leverages its suite of technologies both in strategic collaborations and in maximizing the value of its proprietary products. argenx pursues collaborations on product candidates whose therapeutic potential is in disease areas or patient populations better served by the resources of larger biopharmaceutical companies.

Additionally, argenx is actively seeking to in-license third-party product candidates where it can create value through its technologies and expertise.

argenx is building long-term collaborations with leading academic specialists through its Innovative Access Program (IAP). The IAP expedites the validation of new targets to accelerate the creation of new product candidates for its pipeline.

For more information on partnering opportunities, please contact:

Debbie Allen, PhD
Sr VP Business Development

Arjen Lemmen
Sr Director Corporate Development